
Quarterly report 2022-Q1
added 06-27-2022
Dr. Reddy's Laboratories Limited EPS Ratio 2011-2026 | RDY
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Dr. Reddy's Laboratories Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 104 | 118 | 113 | 59.1 | 72.2 | 117 | - | - | - | - | - |
All numbers in INR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 118 | 59.1 | 97.3 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
AbCellera Biologics
ABCL
|
-0.49 | $ 3.55 | -0.28 % | $ 1.06 B | ||
|
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | ||
|
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | ||
|
AC Immune SA
ACIU
|
-0.97 | $ 3.26 | 4.15 % | $ 229 M | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-3.51 | - | 10.36 % | $ 9.8 M | ||
|
Aptorum Group Limited
APM
|
-0.78 | $ 0.79 | 0.05 % | $ 4.31 M | ||
|
ADC Therapeutics SA
ADCT
|
-3.77 | $ 4.14 | -1.9 % | $ 105 M | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-2.4 | $ 6.55 | -1.16 % | $ 179 M | ||
|
argenx SE
ARGX
|
-7.99 | $ 711.17 | 1.12 % | $ 25 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.43 | -4.99 % | $ 8.25 B | ||
|
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | ||
|
Ascendis Pharma A/S
ASND
|
-8.28 | $ 230.22 | -0.35 % | $ 5 B | ||
|
BioCardia
BCDA
|
-0.55 | $ 1.3 | 1.97 % | $ 27.5 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
Atea Pharmaceuticals
AVIR
|
-1.94 | $ 6.12 | 1.16 % | $ 499 M | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
Athersys
ATHX
|
-0.39 | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | ||
|
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | ||
|
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 3.43 | -4.19 % | $ 7.46 B | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
Catalyst Biosciences
CBIO
|
0.06 | $ 11.3 | -2.46 % | $ 1.01 B | ||
|
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | ||
|
Anika Therapeutics
ANIK
|
-5.64 | $ 14.59 | 1.6 % | $ 214 M | ||
|
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | ||
|
Aptose Biosciences
APTO
|
-36.4 | - | -45.71 % | $ 1.2 M | ||
|
CNS Pharmaceuticals
CNSP
|
-38.9 | $ 2.4 | -2.04 % | $ 917 K | ||
|
AVEO Pharmaceuticals
AVEO
|
-1.63 | - | - | $ 521 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-2.16 | $ 2.63 | -0.57 % | $ 16.5 M | ||
|
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-0.86 | $ 1.52 | 0.33 % | $ 388 M | ||
|
BioNTech SE
BNTX
|
42.2 | $ 94.73 | 4.62 % | $ 27.2 B | ||
|
Athira Pharma
ATHA
|
-2.52 | - | - | $ 269 M | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M |